SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the 2024 Maxim Healthcare Virtual Summit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. David Angulo, M.D., President and CEO of SCYNEXIS, will engage in a fireside chat on Thursday, October 17, at 11:30 A.M. ET.
The event will be held virtually, and interested parties can sign up to view the presentation through a provided link. Additionally, one-on-one investor meetings will be available after the event upon request, which can be arranged through a separate link or by contacting a Maxim representative.
Details
News Market Reaction – SCYX
The recorded move for SCYX in the trading session of this news was +2.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET.
| Maxim Healthcare Virtual Summit Details: | |
| Format: | Fireside chat |
| Date: | Thursday, October 17, 2024 |
| Time: | 11:30 A.M. ET |
| Location: | Virtual |
To sign up to view the presentation, click here.
1x1 investor meetings will be available after the event upon request through the following link or by contacting your Maxim representative.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.